GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novaccess Global Inc (OTCPK:XSNX) » Definitions » Return-on-Tangible-Equity

XSNX (Novaccess Global) Return-on-Tangible-Equity : 0.00% (As of Jun. 2024)


View and export this data going back to . Start your Free Trial

What is Novaccess Global Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Novaccess Global's annualized net income for the quarter that ended in Jun. 2024 was $-3.74 Mil. Novaccess Global's average shareholder tangible equity for the quarter that ended in Jun. 2024 was $-7.14 Mil. Therefore, Novaccess Global's annualized Return-on-Tangible-Equity for the quarter that ended in Jun. 2024 was N/A%.

The historical rank and industry rank for Novaccess Global's Return-on-Tangible-Equity or its related term are showing as below:

XSNX's Return-on-Tangible-Equity is not ranked *
in the Biotechnology industry.
Industry Median: -43.48
* Ranked among companies with meaningful Return-on-Tangible-Equity only.

Novaccess Global Return-on-Tangible-Equity Historical Data

The historical data trend for Novaccess Global's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novaccess Global Return-on-Tangible-Equity Chart

Novaccess Global Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Return-on-Tangible-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only Negative Tangible Equity - - - -

Novaccess Global Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - Negative Tangible Equity - -

Competitive Comparison of Novaccess Global's Return-on-Tangible-Equity

For the Biotechnology subindustry, Novaccess Global's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novaccess Global's Return-on-Tangible-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Novaccess Global's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Novaccess Global's Return-on-Tangible-Equity falls into.


;
;

Novaccess Global Return-on-Tangible-Equity Calculation

Novaccess Global's annualized Return-on-Tangible-Equity for the fiscal year that ended in Sep. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Sep. 2023 )  (A: Sep. 2022 )(A: Sep. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Sep. 2023 )  (A: Sep. 2022 )(A: Sep. 2023 )
=-4.725/( (-4.653+-7.798 )/ 2 )
=-4.725/-6.2255
=N/A %

Novaccess Global's annualized Return-on-Tangible-Equity for the quarter that ended in Jun. 2024 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Jun. 2024 )  (Q: Mar. 2024 )(Q: Jun. 2024 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Jun. 2024 )  (Q: Mar. 2024 )(Q: Jun. 2024 )
=-3.744/( (-6.854+-7.425)/ 2 )
=-3.744/-7.1395
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Jun. 2024) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


Novaccess Global  (OTCPK:XSNX) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


Novaccess Global Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of Novaccess Global's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Novaccess Global Business Description

Traded in Other Exchanges
N/A
Address
8485 Eastern Washington Street, No. 127, Chagrin Falls, OH, USA, 44023
Novaccess Global Inc is a biopharmaceutical company that is developing novel immunotherapies to treat brain tumor patients in the United States. The company's team of experts is working to strengthen the capability of the human body's defense against cancer.
Executives
Jason Michael Anderson director 8584 E. WASHINGTON STREET, NO. 127, CHAGRIN FALLS OH 44023
John Cassarini director 880 WINTER STREET, BUILDING 4, WALTHAM MA 02451
Neil J Laird officer: Chief Financial Officer
Larry Michael Yukich officer: Chief Financial Officer 8834 MAYFIELD ROAD, SUITE C, CHESTERLAND OH 44026
Dwain Morris-irvin officer: Chief Executive Officer 8834 MAYFIELD ROAD, SUITE C, CHESTERLAND OH 44026
Innovest Global, Inc. 10 percent owner 8834 MAYFIELD ROAD, CHESTERLAND OH 44026
Daniel G. Martin director, 10 percent owner, officer: Chief Executive Officer 8834 MAYFIELD RD, CHESTERLAND OH 44026
Michael A Russak director
Osmund Mark Fundingsland director 1237 LAS PALMAS DR, SANTA BARBARA CA 93110
Thomas A Anderson director 2116 PASEO PRIMERO, SANTA FE NM 87501
Jeff J Huitt officer: CFO 10651 WEST 34TH PLACE, WHEAT RIDGE CO 80033
Joseph Grimes officer: COO 6 CLEOME, LADERA RANCH CA 92694
Tom M Djokovich director, 10 percent owner, officer: President 23332 VISTA CARILLO, LAGUNA NIGUEL CA 92677
Brian Altounian director, officer: Secretary 626 N. DOHENY DRIVE, WEST HOLLYWOOD CA 90069
Thomas Djokovich director, officer: President 1601 CLOVERFIELD BLVD, 2ND FL. S. TOWER, SANTA MONICA CA 90404